Poly Medicure Limited — Important, 03-02-2025: Financial Result Updates

Poly Medicure Limited’s board has approved the unaudited consolidated financial results for the third quarter and nine months ended December 31, 2024.

Total revenue for the quarter stood at ₹42,421.19 crore, reflecting an impressive year-over-year growth of approximately 25.4%. This growth can be attributed to increasing global demand for medical devices and successful market expansion strategies in key regions.

Net profit for the quarter reached ₹11,208.97 crore, representing a substantial year-on-year improvement from ₹8,208.97 crore, driven by effective cost management and an uptick in sales volume. Earnings per share (EPS) are reported at ₹9.57, up from ₹8.48 in the corresponding period last year.

Operational costs increased by 11%, mainly due to rising material costs and increased investments in research and development. However, the management's focus on efficiency is evident in their ability to maintain a strong profit margin amidst these challenges.

The balance sheet remains robust, with significant cash flow generation supporting ongoing operations and strategic investments. As of December 31, liquidity appears stable, enhancing the company’s capacity for future growth initiatives.

Looking ahead, Poly Medicure Limited is well-positioned to capitalize on ongoing market opportunities, albeit with potential risks tied to fluctuating input costs and global economic conditions. Assessing this performance, the view is to consider the stock for a buy given the strong fundamentals and growth potential in the evolving healthcare landscape.